FDA approved Siliq (brodalumab), as an injection for the treatment of adults with moderate-to-severe plaque psoriasis. Siliq is intended for patients receiving systemic therapy or phototherapy and have failed to respond other systemic therapies.
Psoriasis is an autoimmune disorder which more commonly occurs in patients with a family history of the disease and most often in people 15 to 35 years of age. Psoriasis cause patches of red skin and flakes. Plaque psoriasis is most common form of psoriasis causing thick, red flaky skin, silver-white scales.
Brodalumab inhibits the inflammatory response responsible for the development of plaque psoriasis by binding to a protein which cause inflammation.
The safety and efficacy of Siliq was established in 3 randomized, placebo-controlled clinical trials of 4,373 adult participants with moderate-to-severe plaque psoriasis who received systemic therapy or phototherapy. Patients treated with Siliq had clear or almost clear skin compared to placebo as evaluated by scoring of the e...